secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-06-25T20:30:12+00:00
Accession:  0001104659-26-077790
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix shareholders approve director elections, executive compensation, stock plan increase, auditor ratification
--------------------------------------------------------------------------------

- Elected eight directors: each with >28.7M votes; broker non-votes 10.7M for each.
- Advisory approval of executive compensation: 28.4M for, 6.7M against, 0.2M abstain.
- Approved stock plan amendment increasing authorized shares from 17.5M to 21.0M shares (28.2M for, 7.0M against).
- Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2026: 42.96M for, 2.0M against, 1.0M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/0001104659-26-077790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/plx-20260625x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-077790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer